A Phase 1/ 2 Study of the TRK Inhibitor LOXO 195 in Adult Subjects With NTRK Fusion (Previously Treated) or Non-Fusion NTRK Altered Cancers

Trial Profile

A Phase 1/ 2 Study of the TRK Inhibitor LOXO 195 in Adult Subjects With NTRK Fusion (Previously Treated) or Non-Fusion NTRK Altered Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs LOXO 195 (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Loxo Oncology
  • Most Recent Events

    • 03 Jun 2017 According to a Loxo Oncology media release, clinical proof-of-concept data from the first two patients treated has been published online.
    • 03 Jun 2017 Status changed from planning to recruiting, according to a Loxo Oncology media release.
    • 30 May 2017 According to a Loxo Oncology media release, the United States Food and Drug Administration has cleared the Investigational New Drug (IND) application for LOXO-195 and planning to initiate Phase 1/2 trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top